Serodus announces randomization of first patients in Phase IIa clinical trial of SER150 in patients with Diabetic Nephropathy

Serodus, today announced that the first patients are randomized in the SER150 multi-center, double-blind, randomized, placebo controlled Phase IIa clinical trial in patients suffering from Diabetic nephropathy. SER150 is a first-in-class anti-inflammatory compound, with a dual anti thrombotic mode of action.

The Phase IIa, safety and tolerability trial is expected to enroll up to total 76 patients, randomized in a 2:1 ratio to either SER150 or placebo treatment. The primary endpoint will be safety and tolerability of SER150. Secondary endpoints will include proteinuria and measurement of urinary thromboxane as a marker of the inflammatory process.

 

"The initiation of this study represents an important milestone for Serodus and for patients suffering from Diabetic nephropathy," said Eva Steiness, Professor, Chief Executive Officer of Serodus. “We believe SER150 has the potential to improve treatment of nephropathy in diabetic patients”.

 

For more information contact:

 

Tore Kvam

CFO, Serodus ASA

Mobile: +47 959 34 199

e-mail: tore.kvam@serodus.com

 

Serodus ASA is a drug development company listed on Oslo Stock Exchange, focusing on new therapeutic products for the treatment of cardiovascular and metabolic diseases with large unmet clinical needs. The company's business model is to seek partnering with international pharmaceutical companies after having demonstrated clinical effect in humans. For more information see www.serodus.